Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen

Breast Cancer Research and Treatment

Volumn 107, Issue 1, 2008, Pages 71-78

  Khoshnoud, Mahmoud R ^a   Fornander, Tommy ^a   Johansson, Hemming ^a   Rutqvist, Lars Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant therapy; Breast cancer; Disease recurrence; Hormone receptors; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; GOSERELIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; EARLY CANCER; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MULTIMODALITY CANCER THERAPY; PHENOTYPE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PHENOTYPE; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECURRENCE; TAMOXIFEN;

EID: 36549036099     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9520-0     Document Type: Article

References (31)

1. Oxford overview, Chemotherapy and hormonal therapy for early breast cancer:effect on recurrence and 15-year survival in an overview of the randomised trials by Early breast cancer trialists' collaborative group (EBCTCG). December 2004
2. Rutqvist LE et al (1987) The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10(3):255-266
3. Rutqvist LE et al (1989) The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 7(1(EBCTCG), E.b.c.t.c.g., Chemotherapy and hormonal therapy for early breast cancer: effects on recurrence and 15-year survival in an overview of the r 0):1474-1484
4. Stockholm Breast Cancer Study Group (1992) Stockholm adjuvant breast cancer trials 5-8, Stockholm, Sweden, Oncologic Centre
5. Wrange O et al (1976) Isoelectric focusing of estradiol receptor protein from human mammary carcinoma - a comparison to sucrose gradient analysis. Eur J Cancer 12(9):695-700
6. Wrange O, Nordenskjold B, Gustafsson JA (1978) Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem 85(2):461-475
7. Ferno M, Borg A, Norgren A (1983) A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. Anticancer Res 3(4):243-246
8. Ferno M, Borg A, Sellberg G (1986) Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 25(3):171-175
9. Burton K (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of DNA. Biochem 62:315-322
10. Marubini E, Valsecchi MG (1995) Analysing survival data from clinical trials and observational studies. John Willey and sons. capital 10:331-361
11. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343-346
12. Knight WA et al (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37(12):4669-4671
13. Maynard PV et al (1978) Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38(11 Pt 2):4292-4295
14. Crowe JP Jr et al (1991) Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 173(4):273-278
15. Crowe JP et al (1982) Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 2(2):171-176
16. Logan LA et al (1982) The estrogen receptor test: a prognostic tool in primary breast cancer. Can J Surg 25(5):581-584
17. Aamdal S et al (1984) Estrogen receptors and long-term prognosis in breast cancer. Cancer 53(11):2525-2529
18. Parl FF et al (1984) Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54(10):2237-2242
19. Donegan WL (1992) Prognostic factors. Stage and receptor status in breast cancer. Cancer 70(6 Suppl):1755-1764
20. Raemaekers JM et al (1985) Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 6(2):123-130
21. Todd JH et al (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56(4):489-492
22. Clark GM et al (1989) Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320(10):627-633
23. Osborne CK et al (2001) Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 7(12 Suppl):4338s-4342s discussion 4411s-4412s
24. Skog S et al (2004) Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumour Biol 25(1-2):41-47
25. Gruvberger S et al (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61(16):5979-5984
26. Dickson RB, Lippman ME (1995) Drug and hormonal resistance in breast cancer, cellular and molecular mechanism. Ellis Horwood Ltd., New York
27. Stal O et al (1994) Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Cytometry 16(2):160-168
28. Rosanelli GP et al (1995) Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters. Anticancer Res 15(2):581-586
29. Corte MD et al (2005) Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance. Breast Cancer Res Treat 90(1):33-40
30. Rodriguez J et al (2005) Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer. Int J Biol Markers 20(2):103-111
31. Aaltonen M et al (1995) Prognostic value of cathepsin-D expression in female breast cancer. Anticancer Res 15(3):1033-1037